title: Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines.
abstract: Lung cancer, the most prevalent cancer worldwide and malignant mesothelioma are highly aggressive tumors that are characterized by high levels of matrix metalloproteinase (MMP)-2 and -9 secretion. Proteases play a key role in tumor cell invasion and metastasis by digesting the basement membrane and ECM components. Strong clinical and experimental evidence demonstrates association of elevated levels of u-PA and MMPs with cancer progression, metastasis and shortened patient survival. MMP activities are regulated by specific tissue inhibitors of metalloproteinases (TIMPS). Our main objective was to study the effect of a nutrient mixture (NM) on the activity of u-PA, MMPs and TIMPs on human lung and malignant mesothelioma (MM) cell lines. Human lung cancer (A-549 and Calu-3) and malignant mesothelioma (MSTO-211H) cell lines were cultured in their respective media and treated at confluence with NM at 0, 50, 100, 250, 500 and 1000 µg/ml. Analysis of u-PA activity was carried out by fibrin zymography, MMPs by gelatinase zymography and TIMPs by reverse zymography. Both lung cancer cell lines expressed u-PA, which was inhibited by NM in a dose-dependent manner. However, no bands corresponding to u-PA were detected for the MSTO-211H MM cell line. On gelatinase zymography, A-549 cells showed one band corresponding to MMP-2 and induction of MMP-9 with PMA (100 ng/ml) treatment. MSTO-211H showed two bands, an intense band corresponding to MMP-2 and a faint band corresponding to MMP-9; MMP-9 was enhanced significantly with PMA treatment. NM inhibited their expression in both cell lines in a dose-dependent manner. Calu-3 showed no MMP-2 or MMP-9 expression. Activity of TIMPs was upregulated by NM in all cancer cell lines in a dose-dependent manner. Analysis revealed a positive correlation between u-PA and MMPs and a negative correlation between u-PA/MMPs and TIMPs. These findings suggest the therapeutic potential of NM in the treatment of lung and mesothelioma cancers.
authors.affiliation: Dr Rath Research Institute, Santa Clara, CA 95050, USA.
authors.forename: M Waheed
authors.initials: MW
authors.lastname: Roomi
authors.forename: Tatiana
authors.initials: T
authors.lastname: Kalinovsky
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Niedzwiecki
authors.forename: Matthias
authors.initials: M
authors.lastname: Rath
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D019587:Dietary Supplements; D006801:Humans; D008175:Lung Neoplasms / Q000178:diet therapy / Q000378:metabolism* / Q000473:pathology; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D008654:Mesothelioma / Q000178:diet therapy / Q000378:metabolism* / Q000473:pathology; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D019714:Tissue Inhibitor of Metalloproteinases; D014568:Urokinase-Type Plasminogen Activator; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
references.citation: Br J Cancer. 2003 May 19;88(10):1553-9
references.pmid: 12771921
references.citation: Prostate. 1997 Aug 1;32(3):188-95
references.pmid: 9254898
references.citation: Int J Biol Markers. 1999 Oct-Dec;14(4):268-71
references.pmid: 10669958
references.citation: Annu Rev Med. 1997;48:489-509
references.pmid: 9046979
references.citation: Cancer Metastasis Rev. 1990 Dec;9(4):289-303
references.pmid: 1965794
references.citation: Exp Lung Res. 2006 Oct;32(9):441-53
references.pmid: 17162651
references.citation: Anticancer Res. 1998 Jul-Aug;18(4A):2487-93
references.pmid: 9703897
references.citation: J Urol. 2003 Sep;170(3):773-6
references.pmid: 12913695
references.citation: Dig Dis Sci. 2003 Jan;48(1):230-7
references.pmid: 12645815
references.citation: Med Electron Microsc. 2002 Mar;35(1):16-23
references.pmid: 12111403
references.citation: Surg Oncol Clin N Am. 2001 Apr;10(2):383-92, x
references.pmid: 11382593
references.citation: Lab Invest. 1983 Aug;49(2):140-7
references.pmid: 6348406
references.citation: Tumour Biol. 2002 May-Jun;23(3):179-84
references.pmid: 12218298
references.citation: Am J Respir Crit Care Med. 2010 Mar 15;181(6):611-9
references.pmid: 20056905
references.citation: Oncol Rep. 2010 Sep;24(3):747-57
references.pmid: 20664983
references.citation: Nature. 1980 Mar 6;284(5751):67-8
references.pmid: 6243750
references.citation: Anticancer Res. 2001 Jan-Feb;21(1A):213-9
references.pmid: 11299737
references.citation: Cancer Metastasis Rev. 2010 Sep;29(3):529-42
references.pmid: 20717705
references.citation: Cancer Lett. 1996 Jun 5;103(2):183-9
references.pmid: 8635156
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9
references.pmid: 16157892
references.citation: Am J Physiol. 1995 Jun;268(6 Pt 1):L972-82
references.pmid: 7611439
references.citation: Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
references.pmid: 12516034
references.citation: Nutr Hosp. 1995 Nov-Dec;10(6):368-72
references.pmid: 8599623
references.citation: Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51
references.pmid: 10357558
references.citation: Br J Cancer. 1982 Sep;46(3):354-67
references.pmid: 7126425
references.citation: Anticancer Drugs. 1996 Jun;7(4):461-8
references.pmid: 8826614
references.citation: Anticancer Res. 2004 Nov-Dec;24(6):4147-61
references.pmid: 15736466
references.citation: Exp Oncol. 2010 Dec;32(4):243-8
references.pmid: 21270751
references.citation: Am J Pathol. 1995 Nov;147(5):1318-29
references.pmid: 7485395
references.citation: J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70
references.pmid: 9293916
references.citation: J Clin Oncol. 2000 Mar;18(5):1135-49
references.pmid: 10694567
references.citation: Am J Clin Nutr. 2000 Jun;71(6 Suppl):1698S-702S; discussion 1703S-4S
references.pmid: 10837321
references.citation: Adv Cancer Res. 1985;44:139-266
references.pmid: 2930999
references.citation: Int J Cancer. 1997 Jul 3;72(1):1-22
references.pmid: 9212216
references.citation: FASEB J. 1990 Apr 1;4(6):1577-90
references.pmid: 2180767
references.citation: Nat Rev Cancer. 2002 Mar;2(3):161-74
references.pmid: 11990853
references.citation: Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92
references.pmid: 12007600
references.citation: Clin Chem. 1998 Jun;44(6 Pt 1):1177-83
references.pmid: 9625040
references.citation: Int J Urol. 2003 Mar;10(3):160-6
references.pmid: 12622713
references.citation: J Biol Chem. 2001 Jun 8;276(23):20085-92
references.pmid: 11274215
references.citation: Cancer Lett. 1992 Jul 31;65(1):51-4
references.pmid: 1511409
references.citation: Carcinogenesis. 1998 Apr;19(4):611-6
references.pmid: 9600345
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2712-25
references.pmid: 19414669